- The European Commission has approved AstraZeneca plc AZN and Sanofi SA’s SNY Beyfortus (nirsevimab) long-acting antibody to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.
- Beyfortus is the first and only single-dose RSV passive immunization for the broad infant population, including those born healthy, at term or preterm, or with specific health conditions.
- In the pivotal MELODY efficacy trial, Beyfortus met its primary endpoint of reducing the incidence of medically attended lower respiratory tract infections (LRTI) caused by RSV by 74.5% vs. placebo through day 151 with a single dose.
- Beyfortus also demonstrated a comparable safety and tolerability profile to
- Swedish Orphan Biovitrum AB's BIOVF Synagis (palivizumab) in the MEDLEY Phase 2/3 trial.
- Globally, in 2019, there were approximately 33 million cases of acute lower respiratory infections leading to more than three million hospitalizations. It was estimated that there were 26,300 in-hospital deaths of children younger than five years.
- Price Action: SNY shares are up 0.61% at $43.10, and AZN shares are up 0.15% at $60.02 during the premarket session on the last check Friday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.